Lemaitre Vascular [LMAT] vs Stevanato [STVN] Detailed Stock Comparison
Lemaitre Vascular
NASDAQ
Loading...
Stevanato
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Lemaitre Vascular wins in 9 metrics, Stevanato wins in 10 metrics, with 0 ties. Stevanato appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Lemaitre Vascular | Stevanato | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 45.01 | 41.46 | Stevanato |
| Price-to-Book Ratio | 5.76 | 4.62 | Stevanato |
| Debt-to-Equity Ratio | 51.25 | 29.80 | Stevanato |
| PEG Ratio | 42.53 | 39.38 | Stevanato |
| EV/EBITDA | 30.14 | 26.52 | Stevanato |
| Profit Margin (TTM) | 20.08% | 11.75% | Lemaitre Vascular |
| Operating Margin (TTM) | 25.13% | 15.03% | Lemaitre Vascular |
| EBITDA Margin (TTM) | 25.13% | 15.03% | Lemaitre Vascular |
| Return on Equity | 13.81% | 9.89% | Lemaitre Vascular |
| Return on Assets (TTM) | 7.28% | 5.20% | Lemaitre Vascular |
| Free Cash Flow (TTM) | $37.16M | $-157.80M | Lemaitre Vascular |
| Dividend Yield | 0.98% | N/A | N/A |
| 1-Year Return | 10.17% | 15.89% | Stevanato |
| Price-to-Sales Ratio (TTM) | 8.90 | 5.63 | Stevanato |
| Enterprise Value | $1.96B | $7.87B | Stevanato |
| EV/Revenue Ratio | 8.33 | 5.91 | Stevanato |
| Gross Profit Margin (TTM) | 70.02% | 28.06% | Lemaitre Vascular |
| Revenue per Share (TTM) | $10 | $4 | Lemaitre Vascular |
| Earnings per Share (Diluted) | $2.05 | $0.57 | Lemaitre Vascular |
| Beta (Stock Volatility) | 0.79 | 0.55 | Stevanato |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Lemaitre Vascular vs Stevanato Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Lemaitre Vascular | -2.10% | 13.87% | 9.97% | 13.23% | -6.26% | 0.89% |
| Stevanato | -2.36% | -5.93% | -3.67% | 5.12% | 10.78% | 5.59% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Lemaitre Vascular | 10.17% | 68.46% | 225.16% | 578.03% | 1,438.00% | 1,330.70% |
| Stevanato | 15.89% | 29.69% | 20.13% | 20.13% | 20.13% | 20.13% |
Performance & Financial Health Analysis: Lemaitre Vascular vs Stevanato
| Metric | LMAT | STVN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.09B | $6.45B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 186,980 | 473,220 |
| 90 Day Avg. Volume | 139,390 | 340,687 |
| Last Close | $92.28 | $23.63 |
| 52 Week Range | $71.42 - $109.58 | $17.12 - $28.00 |
| % from 52W High | -15.79% | -15.61% |
| All-Time High | $109.58 (Nov 25, 2024) | $36.30 (Aug 07, 2023) |
| % from All-Time High | -15.79% | -34.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.08% |
| Quarterly Earnings Growth | 0.17% | 0.44% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.12% |
| Operating Margin (TTM) | 0.25% | 0.15% |
| Return on Equity (TTM) | 0.14% | 0.10% |
| Debt to Equity (MRQ) | 51.25 | 29.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $16.02 | $5.12 |
| Cash per Share (MRQ) | $14.11 | $0.38 |
| Operating Cash Flow (TTM) | $58.76M | $240.50M |
| Levered Free Cash Flow (TTM) | $37.70M | $-83,282,857 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.98% | N/A |
| Last 12-Month Dividend | $0.92 | $0.00 |
Valuation & Enterprise Metrics Analysis: Lemaitre Vascular vs Stevanato
| Metric | LMAT | STVN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 45.01 | 41.46 |
| Forward P/E | 42.53 | 39.38 |
| PEG Ratio | 42.53 | 39.38 |
| Price to Sales (TTM) | 8.90 | 5.63 |
| Price to Book (MRQ) | 5.76 | 4.62 |
| Market Capitalization | ||
| Market Capitalization | $2.09B | $6.45B |
| Enterprise Value | $1.96B | $7.87B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.33 | 5.91 |
| Enterprise to EBITDA | 30.14 | 26.52 |
| Risk & Other Metrics | ||
| Beta | 0.79 | 0.55 |
| Book Value per Share (MRQ) | $16.02 | $5.12 |
Financial Statements Comparison: Lemaitre Vascular vs Stevanato
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LMAT | STVN |
|---|---|---|
| Revenue/Sales | $59.87M | $256.60M |
| Cost of Goods Sold | $18.45M | $186.71M |
| Gross Profit | $41.42M | $69.89M |
| Research & Development | $4.10M | $5.93M |
| Operating Income (EBIT) | $12.63M | $34.63M |
| EBITDA | $18.08M | $55.55M |
| Pre-Tax Income | $14.24M | $35.11M |
| Income Tax | $3.23M | $8.60M |
| Net Income (Profit) | $11.01M | $26.51M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LMAT | STVN |
|---|---|---|
| Cash & Equivalents | $25.34M | $90.72M |
| Total Current Assets | $408.11M | $845.47M |
| Total Current Liabilities | $24.75M | $463.26M |
| Long-Term Debt | $182.73M | $312.73M |
| Total Shareholders Equity | $347.57M | $1.42B |
| Retained Earnings | $151.58M | $890.85M |
| Property, Plant & Equipment | $41.34M | $110.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LMAT | STVN |
|---|---|---|
| Operating Cash Flow | $5.69M | $100.69M |
| Capital Expenditures | $-1.38M | $-69.33M |
| Free Cash Flow | $7.66M | $28.05M |
| Debt Repayment | N/A | $-55.75M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | LMAT | STVN |
|---|---|---|
| Shares Short | 1.38M | 2.17M |
| Short Ratio | 9.42 | 7.35 |
| Short % of Float | 0.08% | 0.04% |
| Average Daily Volume (10 Day) | 186,980 | 473,220 |
| Average Daily Volume (90 Day) | 139,390 | 340,687 |
| Shares Outstanding | 22.55M | 272.90M |
| Float Shares | 20.69M | 48.89M |
| % Held by Insiders | 0.09% | 0.02% |
| % Held by Institutions | 0.95% | 1.10% |
Dividend Analysis & Yield Comparison: Lemaitre Vascular vs Stevanato
| Metric | LMAT | STVN |
|---|---|---|
| Last 12-Month Dividend | $0.92 | $0.00 |
| Last 12-Month Dividend Yield | 0.98% | N/A |
| 3-Year Avg Annual Dividend | $0.68 | $0.04 |
| 3-Year Avg Dividend Yield | 0.23% | 0.26% |
| 3-Year Total Dividends | $2.04 | $0.12 |
| Ex-Dividend Date | Aug 21, 2025 | Jun 04, 2024 |